A missed dose, modelled: what happens to liraglutide concentrations over the following fortnight
Half-life, accumulation ratio and time to steady state are three separate quantities, and confusing them produces most of the bad advice in circulation.
Pharmacology
Page 10 of 12 of this archive, newest first.
Page 10
What STEP 4 and SURMOUNT-4 actually established
Weight reduction in the long programmes flattens at roughly sixty to seventy-two weeks. The timing is consistent, predictable and almost never mentioned in advance.
Three weeks off is a fresh start, whether or not you want one
Supply interruption is the commonest cause of unplanned re-titration in this market, and it is almost never framed that way.
Pancreatitis, obstruction, gallbladder: three things nausea can be
Pancreatitis is rare, was adjudicated in the outcome programmes, and did not show the imbalance early case reports suggested.
Adverse events by dose, adverse events by week
Almost every figure in circulation about tolerability comes from six publications. This is what they say.
Background rates, and why they matter for attribution
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
A schedule that bends does not break
Reducing a dose is not going backwards. In a tolerability-limited class it is the mechanism by which the ceiling is found.
What the anaesthetists said, and then said again
The evidence is real, modest, and mostly retrospective. The guidance is correspondingly cautious and has been revised toward individualisation.
Escalating past the approved maximum, examined honestly
Where the curve flattens, what flattens with it, and what does not.
Holding the dose before surgery: for whom, for how long
This is the single interaction with ordinary medical care that patients most need to disclose, and it is the one most often not asked about.
Gastric emptying is a mechanism, not a side effect
The central effects are not a bonus. On the current evidence they are the principal mechanism of weight loss.
Background rates, and why they matter for attribution
A small number of serious gastrointestinal events occur in people taking these drugs. Distinguishing them from the expected effect profile is the most consequential…
Target dose, effective dose, and the distance between them
What the trials measured was continuation against withdrawal. What patients want to know is continuation at a lower dose, and that study has largely not been done.
The incidence tables, read line by line
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
Forty-four per cent: reading the nausea figure properly
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
Reflux, early satiety, and the volume the stomach will accept
A single drug producing both constipation and diarrhoea looks contradictory until the motility data is read properly.
Non-responders, and the honest state of the evidence about them
Receptor pharmacology is strong on average effects and almost silent on individual variation. That gap is where most reader questions live.
A missed dose, modelled: what happens to retatrutide concentrations over the following fortnight
An accumulation model, drawn from published parameters, with its assumptions stated.
A schedule that bends does not break
Every major phase 3 protocol in this class allowed escalation to be delayed for tolerability. Almost no product label explains the mechanics of doing so.
GIP was a failed target for thirty years. Then it was not.
A dual agonist is one molecule with two receptor activities. A co-formulation is two molecules in one pen. The coverage treats them as synonyms.